Recrutamento encerrado
FASE
Número Europeu 2021-005184-42
CLEE011A2412B
A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsored study
Detalhes
Destaques